Paul Scigalla
Direttore Tecnico/Scientifico/R&S presso GENELUX CORPORATION
Profilo
Paul Scigalla is currently the Chief Medical Officer at Genelux Corp.
since 2011 and a Professor at Ruprecht-Karls-Universität Heidelberg since 1992.
He was previously the Executive Vice President at Sugen, Inc. from 1998 to 2001.
He also held the position of Chief Medical Officer at Nuevolution AB and Deutsche Biotech Innovativ AG.
Scigalla obtained his doctorate degree from Humboldt-Universität zu Berlin.
Posizioni attive di Paul Scigalla
| Società | Posizione | Inizio |
|---|---|---|
| GENELUX CORPORATION | Direttore Tecnico/Scientifico/R&S | 01/09/2011 |
| Ruprecht-Karls-Universität Heidelberg | Corporate Officer/Principal | 01/01/1992 |
Precedenti posizioni note di Paul Scigalla
| Società | Posizione | Fine |
|---|---|---|
Sugen, Inc.
 Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2001 |
| NUEVOLUTION AB (PUBL) | Direttore Tecnico/Scientifico/R&S | - |
| DEUTSCHE BIOTECH INNOVATIV AG | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Paul Scigalla
| Humboldt-Universität zu Berlin | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| DEUTSCHE BIOTECH INNOVATIV AG | Finance |
| GENELUX CORPORATION | Health Technology |
| Aziende private | 2 |
|---|---|
Nuevolution AB
 Nuevolution AB Pharmaceuticals: MajorHealth Technology Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark. | Health Technology |
Sugen, Inc.
Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Paul Scigalla
